단계 미표기초청 등록

WEgovy Real World Assessment of Weight Loss in Korea

연구 개요

This study is to investigate the effectiveness and safety of Wegovy (semaglutide) in Korean patients living with obesity in routine clinical practice. The purpose of this study is to investigate the change in body weight and other clinical characteristics related to body weight in patients living with obesity. Participants will be treated with Wegovy (semaglutide) as prescribed by their doctor, in accordance with normal clinical practice. The study will last for about 52 weeks.

스폰서
리드: 노보노디스크
적응증
Obesity
중재
Semaglutide
목표 등록
500
시작일
2025-11-10
완료(예정)
2027-10-31

BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.